Aquestive Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Highlights, Including Tentative Approval for Sympazan™

Aquestive Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Highlights, Including Tentative Approval for Sympazan™
Aquestive Therapeutics Reports Second Quarter 2018 Financial Results and Recent Business Highlights, Including Tentative Approval for Sympazan™

WARREN, N.J., Sept. 4, 2018 /PRNewswire/ -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs, today reported financial results for the second quarter ended June 30, 2018 and provided a business update.

(PRNewsfoto/Aquestive Therapeutics)

"Aquestive has advanced its proprietary development pipeline and continues to advance its commercial organization.  With the proceeds from our recently closed IPO, we are well positioned to take our late stage CNS products, Sympazan and diazepam, to market as they are approved, and to continue our complex molecule development efforts," said Keith J. Kendall, Chief Executive Officer of Aquestive. "Most notably, the tentative approval for Sympazan that we received from the FDA on August 31st is a significant milestone for the company, as well as for the patients and caregivers who seek improved treatment options to manage Lennox-Gastaut Syndrome."

Pipeline Overview and Upcoming Milestones

Aquestive received tentative approval for Sympazan (clobazam) oral film for the treatment of Lennox-Gastaut Syndrome (LGS) from the U.S. Food and Drug Administration (FDA) in line with its assigned Prescription Drug User Fee Act (PDUFA) date of August 31, 2018. Final FDA approval for Sympazan is pending the expiration of the orphan drug exclusivity period for ONFI ®, which is expected in October 2018.

Aquestive completed enrollment for the adult Epilepsy Monitoring Unit (EMU) clinical study for its diazepam oral film formulation and is advancing towards an NDA filing.

Recent Business Highlights

Aquestive completed its initial public offering of common stock on July 25, 2018 at an offering price of $15.00 per share and received aggregate gross proceeds of $73.9 million, inclusive of the partial exercise of the over-allotment option by the underwriters. Net proceeds received from the offering, after deducting underwriters' discount and fees and expenses of the offering, were $63.5 million

Aquestive's Board of Directors appointed Santo "Sandy" Costa as Chairman in line with its plan. Douglas Bratton, who served as Chairman since 2004, will continue to serve as a member of the Board of Directors. Aquestive also appointed Nancy Lurker, an experienced commercial leader in the pharmaceutical industry, to its Board of Directors.

The U.S. District Court for the District of New Jersey granted Aquestive, together with Indivior PLC (LON: INDV) and its U.S. subsidiary, Indivior Inc., a preliminary injunction against Dr. Reddy's Laboratories (DRL), mandating the restrictions of the previously entered temporary restraining order (TRO) remain in place. The preliminary injunction prevents DRL from using, selling, offering to sell, or importing its generic buprenorphine/naloxone sublingual film until further order of the district court or of the appellate court.

Second Quarter 2018 Financial Results

  • Total revenues increased by 25% to $13.9 million for the second quarter of 2018, up from $11.1 million reported in the second quarter of 2017.
  • Manufacturing and supply expenses decreased by 2% to $5.0 million for the second quarter of 2018 from $5.1 million in the same quarter in 2017.
  • Research and development expenses increased by 67% to $8.0 million in the second quarter of 2018 from $4.8 million in the second quarter of 2017.
  • Selling, general and administrative expenses increased to $33.6 million in the second quarter of 2018 from $5.2 million in the same quarter in 2017. Included in the 2018 selling, general and administrative expenses was $24.8 million of one-time compensation costs associated with the issuance of the non-voting common shares and related withholding taxes, which the company elected to pay on behalf of its former performance unit holders.

As of June 30, 2018, cash and cash equivalents were $10.6 million, as compared to $17.4 million as of December 31, 2017. After June 30, 2018, the company received net proceeds from its IPO of $63.5 million

About Aquestive Therapeutics
Aquestive Therapeutics is a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs. Aquestive Therapeutics has a late-stage proprietary product pipeline focused on the treatment of CNS diseases, and is working to advance orally-administered complex molecules that it believes can be alternatives to invasively-administered standard of care therapies. As the leader in developing and delivering drugs via its PharmFilm® technology, Aquestive Therapeutics also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms.

Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate," "believe," "could," "estimate," "expects," "intend," "may," "plan," "potential," "project," "will," "would," or the negative of those terms, and similar expressions, are intended to identify forward-looking statements.  Such statements include, but are not limited to, statements about regulatory approvals and pathways, clinical trial timing and plans, the achievement of clinical and commercial milestones, future financial and operating results, business strategies, market opportunities, financing, and other statements that are not historical facts.

These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to: risks associated with the Company's development work, including any delays or changes to the timing, cost and success of our product development activities and clinical trials; the risks of delays in FDA approval of our drug candidates or failure to receive approval; the risks inherent in commercializing a new product (including technology risks, financial risks, market risks and implementation risks and regulatory limitations); development of our sales and marketing capabilities; the rate and degree of market acceptance of our product candidates; the success of any competing products; the size and growth of our product markets; the effectiveness and safety of our product candidates; risks associated with intellectual property rights and infringement; unexpected patent developments; and other risks and uncertainties affecting the Company including those described in the "Risk Factors" section included in our Registration Statement on Form S-1 declared effective by the SEC on July 24, 2018. As with any pharmaceutical product candidate under development, there are significant risks with respect to the development, regulatory approval and commercialization of new products. Given these uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. We assume no obligation to update our forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise, except as may be required under applicable law.

Media inquiries:
Christopher Hippolyte

Investor inquiries:
Stephanie Carrington



Condensed Consolidated Statements of Operations and Comprehensive Loss 

(in thousands, except per membership interest and per share data amounts)


Three Months Ended
June 30

Six months Ended
June 30






$            13,928

$     11,142

$            37,339

$     27,577

Cost and expenses:

   Manufacture and supply





   Research and development





   Selling, general and administrative





      Total costs and expenses





      Loss from operations





Other income (expenses):

   Interest expense





   Change in fair value of warrant





   Other, net





      Net loss before income taxes





      Income taxes





      Net loss





Dividends on redeemable preferred interests





   Net loss attributable to common shares / members' interests





   Comprehensive loss

$          (36,493)

$      (6,512)

$          (32,394)

$     (8,582)

Net loss per share 

            Net loss per common share - basic and diluted

$              (1.90)

$              (1.89)

Weighted-average number of common shares / membership interests
outstanding - basic and diluted





Condensed Consolidated Balance Sheets

(in thousands, except unit amounts)


June 30,

December 31,




Current assets:

   Cash and cash equivalents

$                           10,638

$                            17,379

   Accounts receivable, net



   Inventories, net



   Prepaid expenses and other current assets



      Total current assets



Property and equipment, net



Intangible assets, net



Other assets



      Total assets

$                           39,841

$                            43,116


Current liabilities:

   Accounts payable and accrued expenses

$                           21,140

$                            14,003

   Deferred revenue



   Loans payable, current



      Total current liabilities



Loans payable, net



Warrant liability



Asset retirement obligations



      Total liabilities



Commitments and contingencies (Note 14)

Redeemable preferred A-3 interests and accrued dividends



Redeemable preferred A-2 interests and accrued dividends



Shareholders' /Members' Deficit

   Preferred A interests, no par value. Authorized 100,000,000 units;

      16,886,750 units issued and outstanding at December 31, 2017 



   Preferred A-1 interests, no par value. Authorized


      100,000,000 units;  21,526,850 units issued and outstanding at December 31, 2017



   Common interests, no par value. Authorized 500,000,000 units;

      121,228,353 units issued and outstanding  at December 31, 2017



   Common stock, $.001 par value. Authorized 350,000,000 shares;

      15,077,647 voting and 4,922,353 non-voting (Note 15) shares issued and outstanding at June 30, 2018



Additional paid-in capital



Accumulated deficit



      Total shareholders'/members' deficit



      Total liabilities and shareholders' / members' deficit

$                           39,841

$                             43,116


Cision View original content with multimedia:

SOURCE Aquestive Therapeutics

This article was written by cool news network.

Get the latest news delivered to your inbox

Follow us on social media networks

PREV Conn's, Inc. Reports Second Quarter Fiscal 2019 Financial Results
NEXT CBi2 Capital Announces First Quarter Financial Results